Category Archives: Transhuman News

Anti-Senescence Therapy Market 2021: Latest Analysis

Los Angeles, United State,March 2021, The study published on the Anti-Senescence Therapy market is a systematic review that includes key parameters and indicators that are crucial to market understanding. The data from the years 2015 to 2020 is used to show the status and size of the market. The report also includes a total market value for the forecast period, along with the CAGR. The introductory chapter, along with the product description and market scope, provides an overview of the Anti-Senescence Therapy industry. The study also analyzes market dynamics in product-related matters along with developments in the growth of the industry.

Anti-Senescence Therapy Market 2021 Research report contains a qualified and in-depth examination of Anti-Senescence Therapy Industry. At first, the report provides the current business situation along with a valid assessment of the Anti-Senescence Therapy Market Analysis. This report is partitioned based on driving Anti-Senescence Therapy Market Top Key players, application and regions. The progressing Anti-Senescence Therapy economic situations are additionally discovered in the report.

Major Key Manufacturers ofAnti-Senescence Therapy Market are:Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan

Request Free Sample Reportwith Complete TOC and Figures & Graphs@https://www.mraccuracyreports.com/report-sample/205864

Market Segment by Type covers:Gene Therapy, Immunotherapy, Others

Market Segment by Applications can be divided into:Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Anti-Senescence Therapy market.

Production, consumption, revenue, market share, and growth rate are the key targets forAnti-Senescence Therapy Market forecast from 2013 to 2026 (forecast) in these regions:

Benefits of buying the report:

Impact Of COVID-19

The most recent report includes extensive coverage of the significant impact of the COVID-19 pandemic on theAnti-Senescence Therapy division. The coronavirus epidemic is having an enormous impact on the global economic landscape and thus on this special line of business. Therefore, the report offers the reader a clear concept of the current scenario of this line of business and estimates the aftermath of COVID-19.

You can buy the complete report@ https://www.mraccuracyreports.com/checkout/205864

There are 15 Chapters to display the Global Anti-Senescence Therapy market

Chapter 1, Definition, Specifications and Classification of Anti-Senescence Therapy, Applications of Anti-Senescence Therapy, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Anti-Senescence Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Anti-Senescence Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Anti-Senescence Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Anti-Senescence Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Gene Therapy, Immunotherapy, Others, Market Trend by Application Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan , Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Anti-Senescence Therapy ;Chapter 12, Anti-Senescence Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Anti-Senescence Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

GetExclusive Discount on this report @https://www.mraccuracyreports.com/check-discount/205864

About us:

MR Accuracy Reportsprovides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us:

Email:[emailprotected]

Website:www.mraccuracyreports.com

See the original post here:
Anti-Senescence Therapy Market Report Research Reports, Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis...

LEEDS, England--(BUSINESS WIRE)-- 4D Pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Companys management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies.

John will be an important addition to 4D pharmas management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expertise as a CFO of several publicly traded life sciences companies will be critical as we further grow our company and global footprint, said Duncan Peyton, Chief Executive Officer of 4D pharma.

John Beck brings over 30 years of experience in financial and biopharmaceutical industry management experience. This includes three previous positions as Chief Financial Officer of publicly traded life sciences companies where he has achieved considerable results in areas including finance, business and corporate development, strategy, and commercialization.

I look forward to contributing the success of 4D pharma at this exciting stage in its development. 4Ds pioneering work to develop promising therapies across a number of disease areas from oncology to the gut-brain axis is clearly differentiated through its MicroRx platform and LBP product candidates, said John Beck, Chief Financial Officer of 4D pharma. With several key data readouts upcoming and our potential listing on NASDAQ, I believe 4D is well positioned to expand and enhance its investor base and drive further shareholder value for the remainder of 2021.

Mr. Beck has extensive investor and public relations, corporate governance, regulatory, and fundraising expertise. Most recently he was the Senior Vice President, Finance and CFO of Ritter Pharmaceuticals from May 2018 to May 2020, where he oversaw its successful merger with Qualigen Therapeutics, Inc. Prior to that, Mr. Beck served as Executive Manager and CEO at Wellspring Water Technologies, LLC and CEO of West Tech Medical, LLC from October 2015 to May 2018. Mr. Beck also was the CFO and Senior Vice President of Finance and Operations of Ardea Biosciences from February 2008 to June 2012, where he raised over $160 million in public financings, executed a $400 million out-licensing transaction with Bayer Pharmaceuticals and completed a $1.2 billion merger with AstraZeneca. Mr. Beck also held positions as Senior Vice President of Finance, Treasurer and CFO of Metabasis Therapeutics, and the Director of Finance at Neurocrine Biosciences, leading both through successful NASDAQ IPOs.

In addition, Mr. Beck currently serves on the Board of Directors of San Diego-based Artelo Biosciences, as a scientific advisor and mentor to the University of San Diegos student-run TRITON fund. Mr. Beck holds a B.A. in Accounting from the University of Washington, Seattle, a degree in theology from a Seattle area seminary and is a licensed CPA (inactive status) in the state of California.

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372), and Blautix in Irritable Bowel Syndrome (IBS) (NCT03721107) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing. The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is currently expected to become effective in early 2021, subject to the satisfaction of closing conditions, including approval of 4D shareholders and Longevity shareholders and the approval by Nasdaq of the listing of ADSs.

For more information, refer to http://www.4dpharmaplc.com.

Forward-Looking Statements

This press release contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding timing of the clinical trial are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in the commencement of the clinical trial and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission (SEC), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Additional Information about the Transaction and Where to Find it

This press release is being made in respect of a proposed business combination involving 4D and Longevity. Following the announcement of the proposed business combination, 4D filed a registration statement on Form F-4 (the Registration Statement) with the SEC which was declared effective on February 25, 2021. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote or approval nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Registration Statement includes a prospectus with respect to 4Ds ordinary shares and ADSs to be issued in the proposed transaction and a proxy statement of Longevity in connection with the merger. The proxy statement/prospectus has been mailed to the Longevity shareholders on or about February 26, 2021. 4D and Longevity also plan to file other documents with the SEC regarding the proposed transaction.

This press release is not a substitute for any prospectus, proxy statement or any other document that 4D or Longevity may file with the SEC in connection with the proposed transaction. Investors and security holders are urged to read the Registration Statement and, when they become available, any other relevant documents that will be filed with the SEC carefully and in their entirety because they will contain important information about the proposed transaction.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SECs website (www.sec.gov). In addition, investors and security holders will be able to obtain free copies of the Registration Statement and other documents filed with the SEC without charge, at the SECs website (www.sec.gov) or by calling +1-800-SEC-0330.

Participants in the Solicitation

Longevity and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Longevitys shareholders with respect to the proposed transaction. Information regarding Longevitys directors and executive officers is available in its annual report on Form 10-K for the fiscal year ended February 29, 2020, filed with the SEC on April 30, 2020. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests is contained in the Registration Statement.

4D and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Longevity in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005053/en/

Original post:
4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team - BioSpace

Its time to stop mythologizing Black women trying to survive in a world that doesnt value them.

Content warning: police violence, Black death

Black women arent your superheroes. We arent selfless vigilantes, watching through the night for signs of trouble. Were not perched on the wings of the city, waiting to swoop in and save white people in distress.

Black women are human amazing, creative, self-sacrificing humans but human nonetheless. We save others to save ourselves.

But continual demands on Black women to act while others do nothing is killing us.

The last 12 months of nonstop political and cultural turmoil a pandemic, constant images of police brutality, contested elections, insurrection have only further proven how invaluable Black women are to society.

These recent affairs have produced countless examples of Black women turned into superhero caricatures by the white gaze; white people are obsessed with us, obsessed with what we can do for them.

Amanda Gorman, the Youth Poet Laureate who spoke at President Bidens inauguration, has been portrayed as a larger-than-life superhero, a magical being meant to save the United States from itself.

Stacey Abrams (with a coalition of other Black women) helped expand voter accessibility in Georgia. Shes being painted as an almost fanciful champion, saving marginalized votes from the evil clutches of voter suppression tactics without so much as breaking a sweat.

Black women, as a collective, helped the Democratic Party crawl to victory in the 2020 presidential election.

Dont get it twisted; these Black women are wholeheartedly brilliant full stop but white people have mythologized them.

Black women have gone from attentive citizens participating in democracy to protect their communities interests to Americas safety net. Shine the Bat-Signal and well be there in 5.

Beyond establishment politics, Black women are also at the front lines of revolutionary work, slaying systems that disproportionately execute Black people.

Black women have led the months of protests, calling for reverence toward Black life (long after supposed white allies fell to the wayside).

Were the ones creating and circulating calls to action. Were the ones making posters for protests. Were the ones giving our time and energy to various marches and rallies.

Black women do the bulk of organizing, leading, and participating in these revolutionary moments as others stand aside and contribute little beyond pledges to do better.

We save democracies. We save our people. All while juggling personal responsibilities and bearing the cross of what it means to be a Black woman in the world.

And yet, despite the deep and abundant ways that Black women serve everyone, no one shows up for us. No one thanks us for the labor we do at least not in any meaningful way.

No one cares about our constant exhaustion given the trauma and pain we carry and what it does to us physically, emotionally, and mentally.

When it comes to opportunities to show up for us and with us, people rarely find the time. Theyre lackluster about showing any solidarity or support for us; the dedication isnt reciprocated.

Historically, movements like first-wave feminism pushed out Black women in fear that our calls for humanity would weaken the overall movement. Even as Black trans women led the queer liberation movement of the 1960s and 70s, their critical involvement is routinely forgotten.

Currently, rallies for #SayHerName have notably fewer attendants. In fact, the hashtag we created to highlight our unique plight has been co-opted and misused, silencing our message.

Vigils honoring Black trans women are quietly circulated and sparsely attended.

Instead of celebrating the work Black women do and the investments we constantly make in others, the world harms us. The world hates us. The world finds new and innovative ways to humiliate, degrade, and commit violence upon us.

People especially white people who self-consciously tweet about thanking Black women use Black women as a steppingstone to continue living a life of ignorant bliss and placidity.

Despite our cultural and political climate demanding that people finally respect the fullness and beauty of Black life, people still find it in their chest to disrespect and dehumanize Black women.

The killings of Breonna Taylor, Nina Pop, and countless other Black women show how disposable we are.

The fact that the officer who killed Breonna Taylor was punished for wanton endangerment (for the bullets that hit a neighboring apartments walls) versus the bullets that sliced through Breonnas body shows how little Black women matter.

Charges were brought for endangering human life as if Breonnas life wasnt snatched without hesitation. Let this sentencing and others without a flake of justice show how Black women are regarded in this life.

Black women are the victims of all kinds of violence.

The violence looks like being categorically harassed on Twitter by all different races of men.

The violence looks like Talib Kweli dedicating hours upon hours of tweeting to harass Maya Moody, a Black woman whom he had a disagreement with.

The violence looks like Black women being disproportionately affected by and dying from domestic violence.

The violence looks like the epidemic of Black trans women being murdered.

The violence looks like Megan Thee Stallion being shot by Tory Lanez and having her fellow music industry colleagues stay silent about her abuse. It looks like people mocking her trauma, calling her a snitch, and making jokes at her expense.

These types of hate and vitriol are specifically reserved for us.

Our physical and mental health is impaired as people stand around and watch us suffer.

Black women are disproportionately affected by mental health conditions like anxiety, having more intense and chronic symptoms compared with our white counterparts.

Our physical pain is routinely downplayed and undertreated by white doctors.

Black women also have a higher risk of developing and dying from illnesses such as heart disease and cancer.

Were often told these health disparities stem from lifestyle factors, despite research that says otherwise.

Our bodies are literally being worn down by the stress we face, further proving that the lived reality of Black women isnt just a trendy political discussion point. Its an all too real public health crisis that erodes at our very being.

The way that the United States continually burdens Black women with its demands for our intelligence, our sympathy, our action, and our myriad other talents, all the while ignoring our well-being and humanity, is a problem.

Its an issue thats literally killing us. As Black women, we have a responsibility to ourselves to practice self-care and preservation. Of course, the practical ability to do this is difficult considering every crisis that plagues anyone will befall us 10 times worse.

Whenever possible, though, we need to draw boundaries and put ourselves first.

And the wave of people who shower us with empty thanks on social media while doing nothing material to protect our welfare also have a responsibility. Simply put: You all need to legitimately and unquestionably ride for us.

You need to give your money to Black women who are on the front lines. You need to give your money to Black women who move through the world, simply trying to survive.

You need to use your platform to decry the injustices Black women suffer, who die at the hands of misogynoir.

You need to listen to Black women, when we tell you we are hurting, when we tell you that you are hurting us.

You need to examine and unlearn your assumptions about what Black women do and do not owe you (spoiler alert: we owe you nothing).

You need to stop treating us like your emergency brake, as if were only placed on this earth to serve.

Black women deserve to experience the fullness of life without being run ragged by the demands of others.

We should be able to live with some dignity without fearing violence or a premature death because of what the world does to us.

Everyone absolutely everyone has a part to play in ensuring that Black women are protected and showing us that we matter.

Gloria Oladipo is a Black woman and freelance writer, musing about all things race, mental health, gender, art, and other topics. You can read more of her funny thoughts and serious opinions on Twitter.

More here:
As Black Women, We Need to Save Ourselves, Not the World - Healthline

The Action Plan of the European Pillar of Social Rights could lead to a profound shift in the enjoyment of human rights in the EU.

The pandemic and the measures taken to combat it have upended many lives. For millions around the world, Covid-19 has brought protracted uncertainty, isolation and hardship, with no end in sight.

The global poverty rate is likely to increase for the first time in 20 years, risking the reversal of substantial gains. The United Nations secretary-general, Antnio Guterres, has called for a global reset as the world continues to reel from the pandemic, which has claimed more than two million lives and some 500 million jobs.

In Europe, the detrimental impact on the right to physical and mental health has been compounded by over-reliance on the institutional care of older persons and persons with disabilities. And those already in a precarious situation have been hit hardest, with women and minorities particularly afflicted.

At the beginning of last week, the Council of the EU adopted conclusions on a human-rights-based post-Covid-19 recovery, restating the indivisibility of all human rights and reaffirming that a socio-economic response with human rights at its core would enable a more sustainable recovery and make systems more resilient to future shocks. A week earlier, in a joint communication on multilateralism from the European Commission and the high representative for foreign affairs and security policy, the EUs commitment to human rights was presented not only as a matter of values but as an essential component of its support for a rules-based international order.

But the commitment must start at homewith a human-rights-based approach to the Action Plan, due tomorrow, to implement the European Pillar of Social Rights agreed in 2017.

"Social Europe publishes thought-provoking articles on the big political and economic issues of our time analysed from a European viewpoint. Indispensable reading!"

Columnist for The Guardian

Thank you very much for your interest! Now please check your email to confirm your subscription.

Expectations are high for the Action Planfor improving working conditions, tackling homelessness and enhancing social protection. Rightly so, because the pandemic has created an unprecedented opportunity for the EU to trigger a seismic shift in the enjoyment of social rights in the union.

An approach that places human beings and their rights at its centrenot as passive recipients of services but as rights-holders with agencyis the only route to a sustainable recovery. The plan should be guided by international human-rights treaties and recommendations, as well as the UNs 2030 Agenda for Sustainable Development.

While states, as primary duty-bearers under international law, carry the main responsibility to respect, protect and fulfil social rights, the role of the EU institutions cannot be overstated. A rights-based approach will not only help close protection gaps for people living in Europe; it will also strengthen coherence among international, regional and national systems and enhance legal certainty for member states and domestic courts.

But this is about more than compliance: international human rights can sharpen the effectiveness of policy interventions. In addition to the EUs own tools, such as the Social Scoreboard, the findings of UN treaty bodies establish a useful baseline as to where countries stand in terms of social rights. As parties to the UN Convention on Economic, Social and Cultural Rights, member states are, after all, bound to implement these norms. In this vein, the Action Plan should also explicitly recognise adequate housing and social protection as matters of human rightsnot as a commodity or as services.

As you may know, Social Europe is an independent publisher. We aren't backed by a large publishing house or big advertising partners. For the longevity of Social Europe we depend on our loyal readers - we depend on you. You can support us by becoming a Social Europe member for less than 5 Euro per month.

Thank you very much for your support!

It is precisely at this time of crisis that solid public participation is needed. Rights-holders should be enabled to participate effectively in the implementation and review of the social pillarespecially representatives of the most marginalised. To collect reliable information on who they are, the Action Plan should call on states to collect data on socio-economic status, disaggregated by age, sex, race/ethnicity, national origin, disability, education and property.

Because of their proximity to the citizen, local and regional authorities should be more involved in formulating policy. Their views on what works and what doesnt, in healthcare, housing or employment, including job creation, are critical to designing and implementing policies that work for all.

Clear quantitative and qualitative targets should be set and accompanied by a robust system to measure results. Indicators already exist to track and assess progresson human rights from the UN Human Rights Office plus those associated with the Sustainable Development Goals. The Action Plan should also envisage transparent and publicly accessible tools to track linked financial allocations and expenditures.

The EU and its member states have been the strongest supporters of national human-rights institutions around the world and should systematically bring them on board in the Action Plan. National human-rights institutions are state-mandated bodies, independent of government, which advise on legislation, monitor human-rights compliance, raise public awareness and help individuals claim their rights. They also act as a bridge to the international human-rights system.

By aligning its internal policies with its vision for external action, as also articulated in the EU Action Plan for Human Rights and Democracy, Europe can lead by example. But internal coherence will also be central to the plans success. Hence, the importance of joined-up implementation with various other EU policies seeking to advance economic and social rights: the Disability Strategy, the Anti-Racism Action Plan, the Gender Equality Strategy, the Child Guarantee, the Youth Guarantee, the Strategic Framework on Roma Equality and Inclusion, and the LGBTI+ Equality Strategy.

We have before us a chance to close serious gaps in the enjoyment of social rights across the region. If this opportunity is seized, it will lead to better and tangible outcomes in the Covid-19 recovery andmost importantlywill guarantee a life of greater dignity for all.

Go here to see the original:
Aligning the social pillar with human rights - Social Europe

Feb. 26, 2021 07:00 UTC

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces that the United States Securities and Exchange Commission (SEC) has declared effective its registration statements on Form F-4 with respect to the issuance of 4D pharma American Depositary Shares (ADSs) to the shareholders of Longevity Acquisition Corporation (NASDAQ: LOAC) (Longevity), a NASDAQ-listed special purpose acquisition company (SPAC), in connection with the previously announced merger between 4D pharma and Longevity.

It is expected that 4D pharma ADSs will begin trading on NASDAQ under the ticker symbol LBPS following completion of the merger, subject to the satisfaction of the conditions to closing in the merger agreement between 4D pharma and Longevity, including approvals of 4D pharma and Longevity shareholders.

As reported in October 2020, the registration statement facilitates the creation of a trading market in the US for ADSs representing the Company's Ordinary Shares. 4D pharmas Ordinary Shares will continue to be admitted to trading on AIM, a market operated by the London Stock Exchange, under the current ticker symbol DDDD.

The Company will send a circular to 4D pharma shareholders in due course in order to convene a General Meeting to, inter alia, approve the merger.

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programmes, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19, and Blautix in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programmes include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing. The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol LBPS is currently expected to become effective in early 2021, subject to approval of 4D Shareholders and Longevity Shareholders.

For more information, refer to https://www.4dpharmaplc.com

Forward-Looking Statements

This press release contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding expected trading of 4D pharma ADSs on NASDAQ and the potential timing thereof, are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in admitting the ADSs to trading on NASDAQ and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission (SEC), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Additional Information about the Transaction and Where to Find it

This press release is being made in respect of a proposed business combination involving 4D and Longevity. Following the announcement of the proposed business combination, 4D filed a registration statement on Form F-4 (the Registration Statement) with the SEC, which Registration Statement has been declared effective by the SEC. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote or approval nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Registration Statement includes a preliminary prospectus with respect to 4Ds ordinary shares and ADSs to be issued in the proposed transaction and a proxy statement of Longevity in connection with the merger. The proxy statement/prospectus will be provided to the Longevity shareholders. 4D and Longevity also plan to file other documents with the SEC regarding the proposed transaction.

This press release is not a substitute for any prospectus, proxy statement or any other document that 4D or Longevity may file with the SEC in connection with the proposed transaction. Investors and security holders are urged to read the Registration Statement and, when they become available, any other relevant documents that will be filed with the SEC carefully and in their entirety because they will contain important information about the proposed transaction.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SECs website (www.sec.gov). In addition, investors and security holders will be able to obtain free copies of the Registration Statement and other documents filed with the SEC without charge, at the SECs website (www.sec.gov) or by calling +1-800-SEC-0330.

Participants in the Solicitation

Longevity and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Longevitys shareholders with respect to the proposed transaction. Information regarding Longevitys directors and executive officers is available in its annual report on Form 10-K for the fiscal year ended February 29, 2020, filed with the SEC on April 30, 2020. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests is contained in the Registration Statement.

4D and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Longevity in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210225005885/en/

More here:
4D Pharma Announces US SEC Declares Registration Statement Effective with Respect to the Issuance of 4D Pharma American Depositary Shares on NASDAQ -...

ALAMEDA, Calif. & PITTSBURGH--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (LyGenesis), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they will proceed to negotiate an agreement for a merger of the two companies. LyGenesis recently received U.S. Food and Drug Administration clearance for its Investigational New Drug application to conduct a Phase 2a clinical trial on the safety, tolerability, and efficacy of its lead cell therapy for patients with end-stage liver disease, with study initiation planned for 2021. The combined companys pipeline would also include thymus, pancreas, and kidney regeneration, in addition to the existing AgeX assets, including UniverCyte, which uses the HLA-G gene to potentially confer low immune observability to cells to suppress rejection of transplanted cells.

About the Proposed Merger

Based on the terms currently being discussed, a newly formed subsidiary of AgeX would merge into LyGenesis. At the closing of the merger, AgeX would issue to LyGenesis stockholders a number of shares of AgeX common stock representing two-thirds of the total number of shares of AgeX common stock to be outstanding immediately following the consummation of the merger on a fully diluted basis, but prior to the issuance of additional shares in a contemplated capital raising transaction following the execution of a merger agreement and contingent on the closing of the merger. Dr. Michael Hufford, who is the current Chief Executive Officer (CEO) of LyGenesis, upon successful merger would become CEO of the entity that survives the transaction (which includes both AgeX and LyGenesis). Under the terms being discussed, if the merger is completed, AgeXs pre-merger stockholders would receive an 80% economic interest in AgeXs induced tissue regeneration or iTR technology; the terms and structure of such economic interest have not yet been determined.

There can be no assurance that the negotiations between AgeX and LyGenesis will result in the execution of a definitive merger agreement on the terms being discussed or at all, or, if a merger agreement is entered into, that the merger will be consummated. The completion of any merger would be subject to approval by a special independent committee of the AgeX Board of Directors and by the respective Boards of Directors of both companies. The merger would also be subject to approval by AgeX stockholders and LyGenesis stockholders, including in each case approval by both a majority of the outstanding shares and by the holders of a majority of the shares not held by Juvenescence Limited.

Juvenescence Limited (Juvenescence) is the largest shareholder of each of AgeX and LyGenesis. Juvenescence beneficially owns approximately 52.7% of the AgeX common stock determined as disclosed in its most recent amendment to its Schedule 13D filed with the Securities and Exchange Commission, and owns approximately 48% of the common stock of LyGenesis (assuming the conversion of its convertible debt into equity). The Chairman of AgeXs Board of Directors, Dr. Gregory Bailey, is the Chief Executive Officer of Juvenescence. Two directors of LyGenesis, James Mellon and David Ellam, are the Chairman and the Chief Financial Officer of Juvenescence, respectively.

This communication is not an offer to sell any securities or a solicitation of any vote or approval and AgeX is not offering to sell, or soliciting an offer to buy, any securities in any state where the offer or sale is not permitted.

This communication is for informational purposes only and does not constitute an offer to sell any shares of AgeX common stock or a solicitation of any vote or approval, nor is it a substitute for a prospectus that may be included in a registration statement that may be filed by AgeX with the Securities and Exchange Commission (the SEC) under the Securities Act of 1933, as amended, with respect to the potential merger transaction, or a proxy statement that may be provided to AgeX stockholders. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ ANY PROSPECTUS OR PROXY STATEMENT FOR THE MERGER TRANSACTION AND ALL OTHER RELEVANT DOCUMENTS THAT AGEX MAY FILE WITH THE SEC, IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. All documents referred to above, if and when filed by AgeX, will be available free of charge at the SECs website (www.sec.gov) or by directing a request to AgeXs Chief Financial Officer at 1101 Marina Village Parkway, Suite 201, Alameda, California 94501 or apark@agexinc.com.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, Facebook, and YouTube.

About LyGenesis, Inc

LyGenesis is a biotechnology company whose cell therapies enable organ regeneration by using a patients lymph nodes as bioreactors to regrow functioning ectopic organs. LyGenesiss cell therapies are engrafted using endoscopic ultrasound procedure, which is associated with decreased medical risks and costs relative to full organ transplantation. LyGenesiss lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease. Its drug development pipeline includes positive preclinical data for thymus, pancreas, and kidney regeneration. Privately held, LyGenesis is headquartered in Pittsburgh, Pennsylvania. To learn more, please visit lygenesis.com.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (copies of which may be obtained at http://www.sec.gov). Further, the potential merger with LyGenesis is subject to additional risks and uncertainties, including (i) negotiation of a definitive merger agreement, (ii) approval of a merger agreement by the respective boards of directors of AgeX and LyGenesis, (iii) approval of the merger agreement by AgeX stockholders, (iv) the satisfaction or waiver of such contractual conditions to the merger as may be included in the merger agreement, (v) the ability of AgeX and LyGenesis to raise additional capital for the merged company, (vi) potential difficulties integrating the business practices and operations of AgeX with the business practices and operations of LyGenesis; including potential difficulties in conforming accounting policies, procedures, internal controls, and financial records of LyGenesis with AgeX, (vii) the uncertain expense and outcome of the planned clinical trial of LyGenesis liver failure treatment, (viii) the cost and risks associated with the development of additional cell therapies in the LyGenesis product pipeline, (ix) unexpected expenditures or assumed liabilities that may be incurred as a result of the merger, (x) inability to accurately forecast the performance of LyGenesis and AgeX as an integrated company, and (xii) expected synergies between LyGenesis and AgeX may be materially different from actual results. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

Follow this link:
AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement - Business Wire